GlaxoSmithKline (GSK) Statistics And Facts (2025)

Preface

GlaxoSmithKline (GSK) Statistics: GlaxoSmithKline (GSK) is one of the world’s leading pharmaceutical and biotechnology companies. It develops medicines, vaccines, and specialty treatments that help millions of people live healthier lives. Based in the United Kingdom, GSK focuses on preventing and treating diseases such as cancer, HIV, respiratory illnesses, and infectious diseases. The company is also a global leader in vaccine development, supplying products to more than 100 countries. With strong investment in research, advanced technology, and new drug discovery, GSK continues to bring innovative healthcare solutions to patients worldwide.

This article highlights the latest GlaxoSmithKline statistics, including revenue, R&D spending, product portfolio, workforce, market performance, and other key company facts.

Expert Selection

1. GSK, founded in 1715, remains one of the world’s oldest pharmaceutical companies and a global leader in vaccines and specialty medicines.
2. The company reported Q1 2026 revenue of GBP 7.6 billion (USD 10.28 billion), up 5% at CER.
3. Specialty Medicines revenue reached GBP 3.2 billion (USD 4.33 billion), driven by strong HIV, respiratory, and oncology growth.
4. Shingrix remained GSK’s top vaccine, generating GBP 1.0 billion (USD 1.35 billion) in Q1 2026 sales, up 20% at CER.
5. Oncology sales surged 28% at CER, supported by growth in Jemperli, Ojjaara, and Blenrep.
6. GSK expanded its cancer pipeline through the USD 10.6 billion acquisition of Nuvalent.
7. The company plans to begin more than 20 late-stage clinical trials by the end of 2026.
8. GSK raised its long-term target of reaching GBP 40 billion (USD 53.2 billion) in annual sales by 2031.
9. The company launched its Accelerate Growth program targeting GBP 1.9 billion (USD 2.52 billion) in annual savings by 2029.
10. GSK continues investing in AI, genomics, and advanced research to accelerate drug discovery and clinical development.

Key Facts About GlaxoSmithKline

• GSK began in 1715, making it one of the oldest pharmaceutical companies in the world.
• In 2022, the company changed its name from GlaxoSmithKline to GSK after separating its consumer healthcare business into Haleon.
• GSK has established itself as a major player in global healthcare through its expertise in vaccines and specialty medicines.
• The company manufactures more than 2 million vaccine doses every day to meet global demand.
• GSK was one of the first pharmaceutical companies to invest heavily in adjuvant technology, which improves vaccine performance.
• During 2025-2026, GSK expanded its oncology business through acquisitions and licensing agreements.
• The company also reported solid growth in its respiratory, HIV, and vaccine businesses.
• GSK continues to use artificial intelligence and genomics to speed up drug discovery and improve clinical development.

GlaxoSmithKline’s Strong Financial Report

• GSK reported Q1 2026 revenue of GBP 7.6 billion (USD 10.28 billion), increasing 2% at AER and 5% at CER.
• Specialty Medicines generated GBP 3.2 billion (USD 4.33 billion), up 14%. Respiratory, Immunology & Inflammation contributed GBP 0.9 billion (USD 1.22 billion, +16%), Oncology delivered GBP 0.5 billion (USD 0.68 billion, +28%), and HIV recorded GBP 1.8 billion (USD 2.43 billion, +10%).
• Vaccines revenue reached GBP 2.1 billion (USD 2.84 billion), up 4%. Shingrix generated GBP 1.0 billion (USD 1.35 billion, +20%), while Meningitis vaccines declined 3% to GBP 0.3 billion (USD 0.41 billion) and Arexvy fell 18% to GBP 0.1 billion (USD 0.14 billion).
• General Medicines generated GBP 2.3 billion (USD 3.11 billion), declining 6%, while Trelegy remained stable at GBP 0.6 billion (USD 0.81 billion).

Profitability and Cash Flow

• Operating profit increased 9%, while earnings per share rose 15%, supported by stronger operating performance and higher income from asset disposals.
• Core operating profit reached GBP 2.65 billion (USD 3.58 billion), up 10%, driven by higher sales, a better product mix, lower SG&A expenses, and increased royalty income.
• Core EPS increased 9% to 46.5p, while the core operating margin improved to 34.7%, up 1.8% at CER.
• Cash generated from operations totaled GBP 1.35 billion (USD 1.82 billion), up 4%, while free cash flow reached GBP 0.8 billion (USD 1.08 billion).

Pipeline and Research Progress

• GSK received approvals for Exdensur in the EU and China, Nucala for COPD in the EU, and Blenrep in China for multiple myeloma.
• Regulatory filings for Bepirovirsen were accepted in the U.S., EU, China, and Japan, with additional clinical data expected in Q2 2026.
• Efimosfermin (FGF21) received U.S. Breakthrough Therapy and EU PRIME designations for MASH liver disease.
• Early Phase I results for the Mo-Rez antibody-drug conjugate supported plans to begin five Phase III trials during 2026.
• Additional late-stage data are expected in 2026 for camlipixant, Jemperli, Q4M HIV PrEP, and Exdensur for EGPA.
• GSK also expanded its pipeline through the acquisitions of ozureprubart and HS235.

Shareholder Returns and Outlook

• GSK declared a Q1 2026 dividend of 17p per share and continues its GBP 2.0 billion (USD 2.70 billion) share buyback program through Q2 2026.
• The company confirmed that its 2026 guidance includes the impact of the U.S. Government agreement providing relief from 100% Section 232 pharmaceutical tariffs until 20 January 2029.
• Based on exchange rates of USD 1.35/GBP, EUR 1.15/GBP, and JPY 215/GBP, GSK expects a 2% reduction in reported revenue growth and a 4% reduction in core operating profit growth for 2026.

GlaxoSmithKline (GSK) Statistics by Specialty Medicines Performance

(Source: gsk.com)

• GSK’s Specialty Medicines business generated GBP 3,226 million (USD 4,364 million) in Q1 2026, increasing 10% at AER and 14% at CER.
• The HIV portfolio recorded GBP 1,824 million (USD 2,467 million) in sales, up 6% at AER and 10% at CER.
• Dovato generated GBP 666 million (USD 901 million), Cabenuva delivered GBP 368 million (USD 498 million), and Apretude contributed GBP 120 million (USD 162 million).
• The Respiratory, Immunology & Inflammation portfolio reported GBP 890 million (USD 1,204 million) in sales, growing 11% at AER and 16% at CER.
• Within this segment, Nucala generated GBP 484 million (USD 655 million), Benlysta recorded GBP 384 million (USD 519 million), and Exdensur contributed GBP 11 million (USD 15 million).

By Oncology Performance

• GSK’s Oncology business generated GBP 512 million (USD 692 million) in Q1 2026, increasing 23% at AER and 28% at CER, supported by wider patient access to Blenrep.
• Jemperli recorded GBP 232 million (USD 314 million) in sales, growing 33% at AER and 40% at CER.
• Ojjaara/Omjjara generated GBP 144 million (USD 195 million), up 29% at AER and 34% at CER.
• Zejula reported GBP 114 million (USD 154 million) in sales, declining 13% at AER and 11% at CER due to weaker demand and pricing pressure in the United States.
• Blenrep contributed GBP 23 million (USD 31 million).

By Vaccines Performance

• GSK’s Vaccines business generated GBP 2,149 million (USD 2,906 million) in Q1 2026, increasing 3% at AER and 4% at CER.
• Shingrix remained the company’s top-performing vaccine, generating GBP 1,026 million (USD 1,388 million) in sales, up 18% at AER and 20% at CER.
• Meningitis vaccines recorded GBP 335 million (USD 453 million) in revenue, declining 4% at AER and 3% at CER.
• Arexvy generated GBP 65 million (USD 88 million) in sales, down 17% at AER and 18% at CER.
• Other pediatric and adult vaccines contributed GBP 713 million (USD 964 million), with sales decreasing 11% at AER and 9% at CER.

By General Medicines Performance

• GSK’s General Medicines business generated GBP 2,254 million (USD 3,048 million) in Q1 2026, declining 9% at AER and 6% at CER.
• The Respiratory portfolio recorded GBP 1,594 million (USD 2,156 million) in sales, down 7% at AER and 4% at CER.
• Trelegy generated GBP 646 million (USD 874 million) in revenue, with sales declining 4% at AER. The company did not report CER growth for the product.
• Other General Medicines contributed GBP 660 million (USD 893 million) in sales, decreasing 15% at AER and 12% at CER.

GlaxoSmithKline Sales Statistics by United States, Q1 2026

• Sales reached GBP 3,737 million (USD 5,054 million), according a official PDF published by GSK.
• At CER, Specialty Medicines grew 16%, driven by HIV, oncology, Benlysta, and Nucala. Vaccines declined 2% due to weaker demand for Arexvy, Bexsero, Menveo, and Infanrix/Pediarix.
• Meanwhile, general Medicines fell 6% because of lower Trelegy volumes, pricing pressure, and increased competition.

By Europe

• Revenue totaled GBP 2,083 million (USD 2,817 million), increasing 19% at AER and 14% at CER.
• Specialty Medicines rose 8%, Vaccines grew 33% on strong Shingrix demand, while General Medicines declined 2%.

By International

• Sales were GBP 1,810 million (USD 2,447 million), declining 10% at AER and 6% at CER.
• Specialty Medicines increased 16%, while Vaccines fell 17% and General Medicines declined 9%.

GSK Share Price Trend

(Source: in.investing.com)

• The bid/ask price is USD 1,960.50/USD 1,961.00.
• The previous close was USD 1,936.50, while the opening price was USD 1,931.00.
• The day’s range is USD 1,931.00-USD 1,961.50.
• The 52-week range is USD 1,389.50-USD 2,282.00.
• Trading volume is 601.92K, below the 3-month average of 8.02 million.
• The asset has gained 41.7209% over one year.

GSK Strengthens Pipeline and Raises Long-Term Growth Targets

• GSK now expects to begin 25 late-stage clinical studies by the end of 2026, up from its earlier target of 10, after identifying 7 experimental medicines for testing across 18 indications, according to Reuters.
• The company raised its mid-term operating margin outlook to “stable to improving”, while maintaining its 2026 sales growth forecast of 3%-5% and expecting results in the upper half of that range.
• GSK completed a USD 10.6 billion acquisition of Nuvalent, with 3 of the 7 priority medicines focused on cancer.
• The company will invest GBP 2.4 billion (USD 3.19 billion) in restructuring and GBP 400 million (USD 532 million) to relocate R&D to Cambridge.

(Source: reuters.com)

• GSK reaffirmed its goal of achieving GBP 40 billion (USD 53.2 billion) in annual sales by 2031 despite recording a GBP 1.33 billion (USD 1.77 billion) impairment charge related to camlipixant.

GSK’s Major Strategic Developments in 2026

• GSK completed the acquisition of Nuvalent on 15 July 2026 for an equity value of GBP 8.0 billion (USD 10.6 billion). Its net investment, after acquired cash, was GBP 7.1 billion (USD 9.4 billion). The acquisition added 3 lung cancer assets: zidesamtinib, neladalkib, and NVL-330.
• According to lse.co.uk, GSK expanded its R&D pipeline to 62 clinical assets, identified 7 priority medicines across 18 indications, and increased its 2026 goal from 10 to more than 20 Phase III trial starts.
• The Accelerate Growth program aims to deliver GBP 1.9 billion (USD 2.52 billion) in annual savings by 2029. GSK expects implementation costs of GBP 2.4 billion (USD 3.19 billion), including GBP 2.1 billion (USD 2.79 billion) in cash costs.
• GSK discontinued camlipixant for refractory chronic cough, resulting in an impairment charge of GBP 1.3 billion (USD 1.73 billion).
• In the 476-patient LATA study, viral rebound was 0.9% (2/235) with Cabenuva versus 6.4% (15/241) with daily oral therapy, while 94% (215/228) of participants found injections easier. In the OPERA study of nearly 6,800 adults, 89% (3,655/4,095) of Cabenuva users achieved viral suppression compared with 83% (2,239/2,699) receiving oral therapy.

Closing

GlaxoSmithKline (GSK) is one of the world’s leading healthcare companies, known for its strong focus on medicines, vaccines, and scientific research. The company continues to develop new treatments while expanding its presence in global markets.

Its steady financial growth, broad product portfolio, and ongoing investment in innovation support its long-term success. As healthcare needs continue to grow, GSK is well-placed to improve patient care and remain a trusted leader in the pharmaceutical industry.